A Study of Valacyclovir to Suppress HSV and HIV Shedding in Coinfected Persons

• Status: Completed
• Trial end date: 2006-06-01
• Target enrollment: 0
• Participant gender: Male

Summary

The primary objective of this research study is to assess if daily valacyclovir therapy for suppression of HSV-2 reactivation is associated with a decrease in mucosal HIV shedding in individuals co-infected with both HSV-2 and HIV.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Washington
• Collaborators: GlaxoSmithKline; National Institutes of Health (NIH)
• Treatments: Acyclovir; Valacyclovir

Criteria

Inclusion Criteria:

• HIV seropositive and HSV-2 seropositive

• MSM (men having sex with men)

• 18 years old or older

Exclusion Criteria:

• Known history of adverse reaction to acyclovir or valacyclovir

• Planned open label use of acyclovir, valacyclovir or famciclovir